Survival estimates by postremission treatment arm (randomization to no further therapy vs GO postremission therapy)
| . | No therapy . | GO . | ||
|---|---|---|---|---|
| At 24 mo . | At 60 mo . | At 24 mo . | At 60 mo . | |
| Overall survival | 45 ± 5 | 21 ± 4 | 45 ± 5 | 28 ± 5 |
| Disease-free survival | 26 ± 4 | 16 ± 4 | 34 ± 4 | 17 ± 4 |
| Relapse probability | 72 ± 4 | 82 ± 4 | 62 ± 5 | 76 ± 4 |
| Nonrelapse mortality | 2 ± 1 | 2 ± 1 | 4 ± 2 | 7 ± 3 |
| . | No therapy . | GO . | ||
|---|---|---|---|---|
| At 24 mo . | At 60 mo . | At 24 mo . | At 60 mo . | |
| Overall survival | 45 ± 5 | 21 ± 4 | 45 ± 5 | 28 ± 5 |
| Disease-free survival | 26 ± 4 | 16 ± 4 | 34 ± 4 | 17 ± 4 |
| Relapse probability | 72 ± 4 | 82 ± 4 | 62 ± 5 | 76 ± 4 |
| Nonrelapse mortality | 2 ± 1 | 2 ± 1 | 4 ± 2 | 7 ± 3 |
Survival estimates are given as mean percentage ± SE. GO indicates gemtuzumab ozogamicin; and mo, months.